In February 2004, the company's name was changed from Icogen Corporation to Icogenex Corporation to reflect a refocusing of the business.
Icogenex is using ICOCEPTTM, its platform technology, to identify therapeutically useful molecules for the treatment of inflammatory diseases, Alzheimer's disease, and diseases involving inappropriate proteolytic processing.
In pursuit of its mission, the company has recruited an experienced research team that has previously made critical contributions to the commercialization of pharmaceutical products, including NovoSeven®, a $1 billion product for Novo Nordisk.
The company's operations have been financed through investments, contracts from other companies, and grant support from the National Institutes of Health. The grant funding is a reflection of the scientific caliber and medical importance of Icogenex projects.
The contract research projects with pharmaceutical companies have demonstrated a proven track record of meeting drug development milestones and timelines. These funds have been invested in developing new technologies, pursuing therapeutic discovery projects, and building the Icogenex operational infrastructure.